BIOMAT Database Logo BIOMAT Database Logo

[The oral 1-25 dihydroxyvitamin D3 pulse therapy in hemodialysis patients for the early treatment of secondary hyperparathyroidism]. 1992

M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Second Department of Internal Medicine, Nippon Medical School.

It is said that maintenance hemodialysis patients are already suffering from secondary hyperparathyroidism (2HPT) from early stage of chronic renal failure. The treatment of 2HPT in this stage is very important for preventing renal osteodystrophy (ROD). But many long-term dialysis patients are still afflicted with ROD although vitamin D have been used for treatment. In this study, an oral administration of 1-25 (OH)2 D3 (4 micrograms) with pulse therapy twice a week at the day before hemodialysis was started for 12 weeks. The concentration of 1-25 (OH)2D3, total calcium (Ca), ionized calcium (Ca++), alkaline phosphatase (ALP) and parathyroid hormone (PHT) in serum were measured not only before and after every 2 hours of administration a day, but also for 12 weeks after that. The peak of serum 1-25 (OH)2D3 could be sufficiently elevated after 8 hours, and the slight peak of Ca++ could be seen after 8 hours as well. But the level of total calcium could not increased. Although the level of only HS-PTH has not increased after 24 hours, a significant reduction in serum level of C-PTH, intact-PTH and HS-PTH could be recognized after 12 weeks finally. This pulse therapy was effective in reducing the serum level of PTH in this early stage from beginning hemodialysis. But, it needs further studies for the standard treatment.

UI MeSH Term Description Entries
D006962 Hyperparathyroidism, Secondary Abnormally elevated PARATHYROID HORMONE secretion as a response to HYPOCALCEMIA. It is caused by chronic KIDNEY FAILURE or other abnormalities in the controls of bone and mineral metabolism, leading to various BONE DISEASES, such as RENAL OSTEODYSTROPHY. Secondary Hyperparathyroidism,Hyperparathyroidisms, Secondary,Secondary Hyperparathyroidisms
D007676 Kidney Failure, Chronic The end-stage of CHRONIC RENAL INSUFFICIENCY. It is characterized by the severe irreversible kidney damage (as measured by the level of PROTEINURIA) and the reduction in GLOMERULAR FILTRATION RATE to less than 15 ml per min (Kidney Foundation: Kidney Disease Outcome Quality Initiative, 2002). These patients generally require HEMODIALYSIS or KIDNEY TRANSPLANTATION. ESRD,End-Stage Renal Disease,Renal Disease, End-Stage,Renal Failure, Chronic,Renal Failure, End-Stage,Chronic Kidney Failure,End-Stage Kidney Disease,Chronic Renal Failure,Disease, End-Stage Kidney,Disease, End-Stage Renal,End Stage Kidney Disease,End Stage Renal Disease,End-Stage Renal Failure,Kidney Disease, End-Stage,Renal Disease, End Stage,Renal Failure, End Stage
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002117 Calcitriol The physiologically active form of vitamin D. It is formed primarily in the kidney by enzymatic hydroxylation of 25-hydroxycholecalciferol (CALCIFEDIOL). Its production is stimulated by low blood calcium levels and parathyroid hormone. Calcitriol increases intestinal absorption of calcium and phosphorus, and in concert with parathyroid hormone increases bone resorption. 1 alpha,25-Dihydroxycholecalciferol,1 alpha,25-Dihydroxyvitamin D3,1, 25-(OH)2D3,1,25(OH)2D3,1,25-Dihydroxycholecalciferol,1,25-Dihydroxyvitamin D3,1 alpha, 25-dihydroxy-20-epi-Vitamin D3,1,25(OH)2-20epi-D3,1,25-dihydroxy-20-epi-Vitamin D3,20-epi-1alpha,25-dihydroxycholecaliferol,Bocatriol,Calcijex,Calcitriol KyraMed,Calcitriol-Nefro,Decostriol,MC-1288,MC1288,Osteotriol,Renatriol,Rocaltrol,Silkis,Sitriol,Soltriol,Tirocal,1 alpha,25 Dihydroxyvitamin D3,1,25 Dihydroxycholecalciferol,1,25 Dihydroxyvitamin D3,1,25 dihydroxy 20 epi Vitamin D3,Calcitriol Nefro,D3, 1 alpha,25-Dihydroxyvitamin,D3, 1,25-Dihydroxyvitamin,D3, 1,25-dihydroxy-20-epi-Vitamin,KyraMed, Calcitriol,MC 1288
D004334 Drug Administration Schedule Time schedule for administration of a drug in order to achieve optimum effectiveness and convenience. Administration Schedule, Drug,Administration Schedules, Drug,Drug Administration Schedules,Schedule, Drug Administration,Schedules, Drug Administration
D005260 Female Females
D006435 Renal Dialysis Therapy for the insufficient cleansing of the BLOOD by the kidneys based on dialysis and including hemodialysis, PERITONEAL DIALYSIS, and HEMODIAFILTRATION. Dialysis, Extracorporeal,Dialysis, Renal,Extracorporeal Dialysis,Hemodialysis,Dialyses, Extracorporeal,Dialyses, Renal,Extracorporeal Dialyses,Hemodialyses,Renal Dialyses
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000284 Administration, Oral The giving of drugs, chemicals, or other substances by mouth. Drug Administration, Oral,Administration, Oral Drug,Oral Administration,Oral Drug Administration,Administrations, Oral,Administrations, Oral Drug,Drug Administrations, Oral,Oral Administrations,Oral Drug Administrations

Related Publications

M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
The 'oral 1,25-dihydroxyvitamin D3 pulse therapy' in hemodialysis patients with severe secondary hyperparathyroidism.
January 1991, Nephron,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
[A trial of suppressing secondary hyperparathyroidism by oral high dose therapy of 1, 25-dihydroxyvitamin D3].
April 1989, Nihon Jinzo Gakkai shi,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Successful treatment of secondary hyperparathyroidism in hemodialysis patients with oral pulse 1-alpha-hydroxy-cholecalciferol therapy.
January 1996, Nephron,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Oral pulse therapy with vitamin D3 for control of secondary hyperparathyroidism.
December 1994, Pediatric nephrology (Berlin, Germany),
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
[Oral calcitriol pulse therapy in treatment of secondary hyperparathyroidism in patients with long term hemodialysis].
January 1996, Przeglad lekarski,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Indication for oral 1,25-dihydroxyvitamin D3 pulse therapy in patients with renal osteodystrophy at hemodialysis induction.
January 1994, Nephron,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Oral vitamin D3 pulse therapy for overt secondary hyperparathyroidism at pre-dialysis stage.
May 1996, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Improvement of anemia in hemodialysis patients after pulse oral 1-alpha-D3 treatment.
June 2002, Clinical nephrology,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Intravenous alfacalcidol once weekly pulse therapy for secondary hyperparathyroidism in hemodialysis patients.
January 2011, Renal failure,
M Kawabe, and M Shimizu, and M Takeuchi, and S Matsunobu, and N Hayama, and Y Iino, and K Hara, and A Terashi
Pharmacokinetics of active vitamins D3, 1 alpha-hydroxyvitamin D3 and 1 alpha, 25-dihydroxyvitamin D3 in patients on chronic hemodialysis.
February 1991, Clinical nephrology,
Copied contents to your clipboard!